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Schizophrenia is a neurodevelopmental disease re-
sulting from abnormal early brain development and/
or impaired postnatal maturation of the brain. Th e 
complex and varying symptoms of the disease indi-
cate that an interplay of multiple factors rather than 
one single factor triggers this illness. Both genetic 
and epigenetic factors have been identifi ed and a hy-
pothesis, the “two hit hypothesis”, has been proposed 
explaining the origins of the disease by at least two 
subsequent etiological “hits”, a genetic predisposition 
and an epigenetic factor. 
Many studies of people with schizophrenia have 
found subtle abnormalities in brain structure or in the 
way it functions caused by disturbances in cell migra-
tion, neurite outgrowth, axon fasciculation, synapse 
formation, and adult neurogenesis. Th ese disturbances 
are in close relations with alterations in neurotrophic 
factors. It was hypothesised that imbalances in the 
neurotrophic system might contribute to alterations 
in the brain which are closely connected with schizo-
phrenia. To further characterise cellular processes 
involved in schizophrenia we studied neurogenesis, 
neurotrophic factors, and eff ects of neuroleptic drugs 
in a developmental model (Vitamin D defi ciency) and 
a pharmacological model (subchronic treatment with 
the non-competitive NMDA receptor antagonist 
ketamine). Developmental models are basing on the 
assumption that damage at a very early stage of onto-
genesis results in structural abnormalities1-3, whereas 
pharmacological models are focusing on alterations in 
specifi c neurotransmitter systems with special regard 
to dopaminergic and glutamatergic systems4,5.
We found that subchronic ketamine treatment as 
well as its withdrawal enhanced the generation and/
or survival of neurons in young-adult animals. On the 
contrary, maternal Vitamin D depletion resulted in 
reduced neurogensis. Th is correlates with alterations 
in the concentration of neurotrophic factors in diff er-
ent brain structures found in the Vitamin D depletion 
model6-8 and in the ketamine model9,10. At the fi rst 
view, our results obtained in the Vitamin D depletion 
model appear to be contrary to results obtained in the 
studies of McGrath’s group6,11, demonstrating an anti-
proliferative potency of vitamin D. However, the ex-
perimental settings diff er in a crucial for neurogenetic 
experiments parameter as they studied the developing 
brain, whereas in our study adult animals were used.
Th e classical neuroleptic haloperidol and the atyp-
ical neuroleptic risperidone had diff erent eff ects on 
schizophrenia-related alterations in the rats’ behav-
iour12-14, alterations in hippocampal long-term poten-
tiation15 and as well as on neurogenesis16.
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